Toronto, Ontario–(Newsfile Corp. – March 17, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has received confirmation of eligibility from The Depository Trust Company (“DTC“) for electronic settlement and transfer of its common shares in the United States. The Company’s common shares are currently listed and posted for trading on the OTCQB® Venture Market (the “OTCQB“) under the symbol “MSSTF” and will continue to trade on the Canadian Securities Exchange under the symbol “MSET” as well as on the Frankfurt Stock Exchange under the symbol “9DF”.
DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. DTC eligibility incorporates an electronic method of clearing securities that speeds up the receipt of stock and cash. This reduces costs and accelerates the settlement process for investors and brokers, allowing the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their clearing and settlement requirements.
James Lanthier, CEO of Mindset commented, “DTC eligibility will provide current and prospective shareholders of Mindset with a reliable, cost-efficient, and timely method for clearing and settlement of Mindset’s common shares. With the Company’s common shares being DTC eligible, we expect this to lead to greater liquidity and execution speeds, as well as Mindset’s common shares being accessible to an even broader range of investors.”
FOR MORE INFORMATION, PLEASE CONTACT:
James Lanthier
Chief Executive Officer
jlanthier@mindsetpharma.com
Jason Atkinson
VP, Corporate Development
jatkinson@mindsetpharma.com
647-938-5266
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.